Outpatient Epcoritamab as 2L in NTE R/R DLBCL

This study is testing epcoritamab — a type of immunotherapy called a bispecific antibody that helps the immune system attack lymphoma cells — as a second-line outpatient treatment for people with a specific type of aggressive blood cancer called diffuse large B-cell lymphoma (DLBCL) that has come back or stopped responding. **You may be eligible if...** - You have been diagnosed with DLBCL or a related large B-cell lymphoma that is not eligible for stem cell transplant - Your lymphoma has returned or stopped responding after one prior treatment that included standard chemotherapy and an anti-CD20 drug (like rituximab) - Your disease is measurable on a PET scan **You may NOT be eligible if...** - You have received more than one prior line of treatment - You are eligible for standard second-line therapy with stem cell transplant - You have significant organ dysfunction or active serious infections Talk to your doctor to see if this trial is right for you.